Tu2020 CNP-104, AN INVESTIGATIONAL ANTIGEN-SPECIFIC NANOPARTICLE THERAPY, DEMONSTRATES FAVORABLE SAFETY AND EARLY SIGNAL OF DISEASE STABILIZATION IN A PHASE 2A RANDOMIZED, PLACEBO- CONTROLLED TRIAL IN PATIENTS WITH PBC, SUPPORTING ADVANCEMENT TO NEXT PHASE TRIALS